Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19:534–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin. 2023;73:255–74.

Article  PubMed  Google Scholar 

Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K. Next generation radiotheranostics promoting precision medicine. Ann Oncol. 2023;34:507–19.

Article  CAS  PubMed  Google Scholar 

Simeon R, Chen Z. In vitro-engineered non-antibody protein therapeutics. Protein Cell. 2018;9(1):3–14.

Article  CAS  PubMed  Google Scholar 

Vadevoo SMP, Gurung S, Lee HS, Gunassekaran GR, Lee SM, Yoon JW, Lee YK, Lee B. Peptides as multifunctional players in cancer therapy. Exp Mol Med. 2023;55:1099–109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J. Affibody molecules in Biotechnological and Medical Applications. Trends Biotechnol. 2017;35:691–712.

Article  PubMed  Google Scholar 

Tolmachev V, Orlova A. Affibody molecules as Targeting vectors for PET imaging. Cancers. 2020;12:651.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339–48.

Article  CAS  PubMed  Google Scholar 

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, Carlsson J, Lindman H. Measuring HER2-Receptor expression in metastatic breast Cancer using [68Ga]ABY-025 affibody PET/CT. Theranostics. 2016;6:262–71.

Article  PubMed  PubMed Central  Google Scholar 

Zhou N, Liu C, Guo X, Xu Y, Gong J, Qi C, Zhang X, Yang M, Zhu H, Shen L, Yang Z. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 2021;48:161–75.

Article  CAS  PubMed  Google Scholar 

Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a Novel 68Ga-HER2 Affibody PET/CT imaging in breast Cancer patients. Front Oncol. 2022;12:894767.

Article  PubMed  PubMed Central  Google Scholar 

Alhuseinalkhudhur A, Lindman H, Liss P, Sundin T, Frejd FY, Hartman J, Iyer V, Feldwisch J, Lubberink M, Rönnlund C, Tolmachev V, Velikyan I, Sörensen J. Human epidermal growth factor receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT predicts early metabolic response in metastatic breast Cancer. J Nucl Med. 2023;64:1364–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Guo X, Wen L, Wang L, Liu F, Song G, Zhu H, Zhou N, Yang Z. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients. Eur J Nucl Med Mol Imaging. 2023;50:2775–86.

Article  CAS  PubMed  Google Scholar 

Bragina O, Chernov V, Larkina M, Rybina A, Zelchan R, Garbukov E, Oroujeni M, Loftenius A, Orlova A, Sörensen J, Frejd FY, Tolmachev V. Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer. Theranostics. 2023;13:4858–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garousi J, Vorobyeva A, Altai M. Influence of several compounds and drugs on the renal uptake of Radiolabeled Affibody Molecules. Molecules. 2020;25:2673.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Altai M, Perols A, Tsourma M, Mitran B, Honarvar H, Robillard M, Rossin R, ten Hoeve W, Lubberink M, Orlova A, Karlström AE, Tolmachev V. Feasibility of Affibody-based Bioorthogonal Chemistry-mediated Radionuclide Pretargeting. J Nucl Med. 2016;57:431–6.

Article  CAS  PubMed  Google Scholar 

Oroujeni M, Tano H, Vorobyeva A, Liu Y, Vorontsova O, Xu T, Westerlund K, Orlova A, Tolmachev V, Karlström AE. Affibody-mediated PNA-Based Pretargeted Cotreatment improves survival of Trastuzumab-treated mice bearing HER2-Expressing xenografts. J Nucl Med. 2022;63:1046–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Vorobyeva A, Orlova A, Konijnenberg MW, Xu T, Bragina O, Loftenius A, Rosander E, Frejd FY, Tolmachev V. Experimental therapy of HER2-Expressing xenografts using the second-generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics. 2022;14:1092.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging. 2009;36:692–701.

Article  PubMed  Google Scholar 

Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773–82.

Article  CAS  PubMed  Google Scholar 

Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. J Nucl Med. 2013;54(6):961–8.

Article  CAS  PubMed  Google Scholar 

Jonsson A, Dogan J, Herne N, Abrahmsén L, Nygren PA. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008;21:515–27.

Article  CAS  PubMed  Google Scholar 

Liu Y, Xu T, Vorobyeva A, Loftenius A, Bodenko V, Orlova A, Frejd FY, Tolmachev V. Radionuclide Therapy of HER2-Expressing xenografts using [177Lu]Lu-ABY-027 Affibody Molecule alone and in combination with Trastuzumab. Cancers (Basel). 2023;15:2409.

Article  CAS  PubMed  Google Scholar 

Liu Y, Güler R, Liao Y, Vorobyeva A, Widmark O, Meuleman TJ, van den Koijen A, Naasz R, Bodenko V, Orlova A, Ekblad C, Tolmachev V, Frejd FY. Biologic evaluation of a heterodimeric HER2-Albumin targeted Affibody Molecule produced by chemo-enzymatic peptide synthesis. Pharmaceutics. 2022;14:2519.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Vorobyeva A, Xu T, Orlova A, Loftenius A, Bengtsson T, Jonasson P, Tolmachev V, Frejd FY. Comparative preclinical evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: impact of DOTA position on ABD Domain. Pharmaceutics. 2021;13:839.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen S, Li B, Xie H, Xu L, Niu G, Fan K, Fan Q. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma. Cancer Biother Radiopharm. 2004;19:589–600.

Article  CAS  PubMed  Google Scholar 

Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529–37.

Article